辰光医疗
(920300)
| 流通市值：6.05亿 | | | 总市值：7.85亿 |
| 流通股本：6619.04万 | | | 总股本：8584.71万 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 69,005,182.6 | 47,964,311.53 | 24,678,348.47 | 89,939,697.09 |
| 营业收入 | 69,005,182.6 | 47,964,311.53 | 24,678,348.47 | 89,939,697.09 |
| 二、营业总成本 | 98,242,829.96 | 66,351,141.36 | 32,480,379.43 | 129,182,046.1 |
| 营业成本 | 36,060,055.38 | 26,202,061.08 | 14,525,916.1 | 43,095,059.93 |
| 税金及附加 | 1,174,436.1 | 800,798.83 | 413,137.76 | 1,835,362.09 |
| 销售费用 | 19,820,879.27 | 13,566,963.67 | 6,502,130.73 | 23,771,189.08 |
| 管理费用 | 16,017,011.08 | 10,266,458.52 | 4,311,212.61 | 22,650,603.49 |
| 研发费用 | 22,096,262.33 | 13,471,164.99 | 5,662,911.46 | 32,744,102.45 |
| 财务费用 | 3,074,185.8 | 2,043,694.27 | 1,065,070.77 | 5,085,729.06 |
| 其中:利息费用 | 2,875,718.31 | 1,904,685.59 | 1,043,521.98 | 4,785,040.42 |
| 其中:利息收入 | 5,919.67 | 4,117.63 | 2,475.74 | 28,334.73 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 41,547.95 | 41,547.95 | - | 253,733.24 |
| 资产处置收益 | 2,422,205.62 | 2,412,626.65 | 30,025.88 | 9,666.95 |
| 资产减值损失(新) | -571,201.89 | -571,201.89 | - | -12,003,233.09 |
| 信用减值损失(新) | 938,623.5 | 871,922.69 | -294,602.51 | -4,292,374.02 |
| 其他收益 | 2,083,197.73 | 1,402,658.56 | 716,088.99 | 3,993,289.39 |
| 四、营业利润 | -24,323,274.45 | -14,229,275.87 | -7,350,518.6 | -51,281,266.54 |
| 加:营业外收入 | 53,601.73 | 50,001.33 | 50,001.31 | 37.14 |
| 减:营业外支出 | 1,602.9 | 1,512.21 | 3,788.26 | 396,685.13 |
| 五、利润总额 | -24,271,275.62 | -14,180,786.75 | -7,304,305.55 | -51,677,914.53 |
| 减:所得税费用 | -3,600,600.03 | -1,268,983.85 | -28,354.88 | 8,762,123.61 |
| 六、净利润 | -20,670,675.59 | -12,911,802.9 | -7,275,950.67 | -60,440,038.14 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -20,670,675.59 | -12,911,802.9 | -7,275,950.67 | -60,440,038.14 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -20,670,675.59 | -12,911,802.9 | -7,275,950.67 | -60,440,038.14 |
| 扣除非经常损益后的净利润 | -24,609,322.94 | -16,244,646.8 | -7,938,739.57 | -63,632,259.72 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.24 | -0.15 | -0.08 | -0.7 |
| (二)稀释每股收益 | -0.24 | -0.15 | -0.08 | -0.7 |
| 九、综合收益总额 | -20,670,675.59 | -12,911,802.9 | -7,275,950.67 | -60,440,038.14 |
| 归属于母公司股东的综合收益总额 | -20,670,675.59 | - | -7,275,950.67 | -60,440,038.14 |
| 公告日期 | 2026-10-29 | 2026-08-26 | 2026-04-29 | 2026-04-24 |
| 审计意见(境内) | | | | 标准无保留意见 |